Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation
Olga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
British Journal of Haematology
|
March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Ronan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
Hagop M Kantarjian, Harry P Erba, David Claxton, et al.
Molecular & Cellular Proteomics : MCP
|
October 9, 2007
Proteomics analysis of cytokine-induced dysfunction and death in insulin-producing INS-1E cells: new insights into the pathways involved
Wannes D'Hertog, Lut Overbergh, Kasper Lage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2007
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
Andrew R Rezvani, Barry Storer, Michael Maris, et al.
Blood
|
October 24, 2002
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
Dietger Niederwieser, Michael Maris, Judith A Shizuru, et al.
Blood Advances
|
October 17, 2024
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network
Minoo Battiwalla, Michael Tees, Ian Flinn, et al.
British Journal of Haematology
|
September 2, 2008
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
Andrew R Rezvani, Lalitha Norasetthada, Ted Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2008
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Mohamed L Sorror, Barry E Storer, Brenda M Sandmaier, et al.
Blood Advances
|
September 30, 2024
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL
Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation
Olga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
British Journal of Haematology
|
March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Ronan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
Hagop M Kantarjian, Harry P Erba, David Claxton, et al.
Molecular & Cellular Proteomics : MCP
|
October 9, 2007
Proteomics analysis of cytokine-induced dysfunction and death in insulin-producing INS-1E cells: new insights into the pathways involved
Wannes D'Hertog, Lut Overbergh, Kasper Lage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2007
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
Andrew R Rezvani, Barry Storer, Michael Maris, et al.
Blood
|
October 24, 2002
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
Dietger Niederwieser, Michael Maris, Judith A Shizuru, et al.
Blood Advances
|
October 17, 2024
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network
Minoo Battiwalla, Michael Tees, Ian Flinn, et al.
British Journal of Haematology
|
September 2, 2008
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
Andrew R Rezvani, Lalitha Norasetthada, Ted Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2008
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Mohamed L Sorror, Barry E Storer, Brenda M Sandmaier, et al.
Blood Advances
|
September 30, 2024
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL
Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, et al.
Page
of 5